# OMX Ventures

OMX Ventures is a Venture Capital based in Lincolnshire, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Lincolnshire, United States
- **Region:** North America
- **Address:** One Overlook Point, Suite 100, Lincolnshire, IL 60069, United States
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** omx.vc
- **LinkedIn:** https://www.linkedin.com/company/omx-ventures

## Regulatory record

- **CRD number:** 313397
- **SEC file number:** 802-121165
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/313397

## About

OMX takes a technology-first approach to grow groundbreaking discoveries into scalable biotech companies on both sides of the Atlantic. It invests at the beginning of a biology revolution enabled by novel Bio-Tools, Data, and Artificial Intelligence that create major new insights in biology. These insights are expected to create the next generation of medicines, tools and solutions.

## Sectors

- Therapeutics
- BioTools & Diagnostics
- Synthetic Bio

## People

- Dan Fero — Managing Director
- Craig Asher — Managing Director
- Nick Haft — Managing Director
- Swetha Murali — Vice President
- Natasha Azar — Vice President Investor Relations
- Tim Richardson — Venture Partner
- John Nawrocki — Chief Financial Officer
- Paul Conley — Venture Partner
- Fred Sweeney — Venture Partner

## Questions

### How does OMX Ventures source and structure its biotech investments?

OMX operates as a technology-first builder VC, taking discoveries from academic or early-stage contexts and standing up scalable companies around them. Rather than participating in large syndicated rounds as a passive minority investor, the firm works to convert platform science into operational businesses, often with a transatlantic dimension linking US and European innovation.

### Does OMX focus on specific therapeutic areas, or is it platform-agnostic?

The firm tags three core buckets — Therapeutics, BioTools & Diagnostics, and Synthetic Biology — but the unifying thesis is platform science. In therapeutics, it has backed mental health (Delix, Compass), women's health (Freya), and cell/gene therapy delivery (Replay). Its tools and synthetic biology holdings span CRISPR diagnostics (VedaBio), proteomics (Glyphic), genome writing (Inscripta, Constructive Bio), and metabolomics (Matterworks).

### Who leads the investment team at OMX Ventures?

OMX does not publicly name its managing partners, investment committee members, or senior investment professionals on its website or in available public filings. The firm's principals remain undisclosed in the sources consulted.

### What is OMX's investment stage and check-size range?

Altss research tags OMX as targeting Early Stage, Seed, and Start-up, but the firm does not publish a minimum or maximum check size. Without a disclosed fund size or deployment figure, specific commitment bands cannot be verified.

### Does OMX invest only in the US, or does it actively deploy in Europe?

The firm positions itself explicitly as operating on both sides of the Atlantic. Portfolio companies include US-domiciled entities as well as UK-headquartered firms such as Constructive Bio, reflecting a geographic mandate that spans North America and Europe.

## Related profiles

- [Omurgacap Asset Management](https://altss.com/profile/omurgacap-asset-management)
- [Ona Capital](https://altss.com/profile/ona-capital)

---

Last updated: 2026-08-11T15:07:41.444Z

Canonical page: https://altss.com/profile/omx-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology